TrialNature communications2024

Sintilimab in combination with stereotactic body radiotherapy and granulocyte-macrophage colony-stimulating factor in metastatic non-small cell lung cancer: The multicenter SWORD phase 2 trial.

Jianjiao Ni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.